These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37747270)

  • 1. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
    Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
    Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
    Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
    Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum.
    Lavatelli F; Brambilla F; Valentini V; Rognoni P; Casarini S; Di Silvestre D; Perfetti V; Palladini G; Sarais G; Mauri P; Merlini G
    Biochim Biophys Acta; 2011 Mar; 1814(3):409-19. PubMed ID: 21215335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
    Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
    Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin free light chain dimers in human diseases.
    Kaplan B; Livneh A; Sela BA
    ScientificWorldJournal; 2011 Mar; 11():726-35. PubMed ID: 21442150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
    Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis.
    Kaplan B; Golderman S; Yahalom G; Yeskaraev R; Ziv T; Aizenbud BM; Sela BA; Livneh A
    J Immunol Methods; 2013 Apr; 390(1-2):74-80. PubMed ID: 23376556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
    Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
    Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
    Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
    Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
    Bomsztyk J; Ravichandran S; Giles HV; Wright N; Berlanga O; Khwaja J; Mahmood S; Wisniowski B; Cohen O; Foard D; Gilbertson J; Rauf MU; Starr N; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore JD; Lachmann H; Harding S; Pratt G; Wechalekar AD
    Blood; 2024 Mar; 143(13):1259-1268. PubMed ID: 38194690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
    Kumar S; Dispenzieri A; Katzmann JA; Larson DR; Colby CL; Lacy MQ; Hayman SR; Buadi FK; Leung N; Zeldenrust SR; Ramirez-Alvarado M; Clark RJ; Kyle RA; Rajkumar SV; Gertz MA
    Blood; 2010 Dec; 116(24):5126-9. PubMed ID: 20798235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient with AL amyloidosis with negative free light chain results.
    Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
    Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
    Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
    Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
    Mahmood S; Wassef NL; Salter SJ; Sachchithanantham S; Lane T; Foard D; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Am J Clin Pathol; 2016 Jul; 146(1):78-85. PubMed ID: 27353767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies.
    Davern S; Tang LX; Williams TK; Macy SD; Wall JS; Weiss DT; Solomon A
    Am J Clin Pathol; 2008 Nov; 130(5):702-11. PubMed ID: 18854262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio.
    Zach D; Ablasser K; Kolesnik E; Hoeller V; Fruhwald F; Prüller F; Reiter C; Beham-Schmid C; Lipp R; Rainer PP; Zirlik A; Wölfler A; Verheyen N
    ESC Heart Fail; 2021 Aug; 8(4):3397-3402. PubMed ID: 33960730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
    Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
    Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
    Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
    Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
    Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.